Recent FDA actions have brought increased attention to several peptide drugs that were only recently removed from the Category 2 bulk substances list. These developments have the potential to reshape how prescribers and compounding pharmacies approach peptide-based treatments, but it has introduced some uncertainty around their compounding eligibility. This article outlines recent regulatory changes, potential compliance risks, and guidance for prescribers navigating the changing landscape of compounded peptides.
Changing Peptide Regulatory Status
A major recent development involves how the FDA categorizes some commonly discussed peptides. These include BPC-157 and TB-500, which were both previously placed in Category 2 of the 503A bulk substances list, indicating FDA safety concerns about impurities.
However, in April 2026, the FDA removed both substances from Category 2 (as well as CJC-1295) following withdrawal of their nominations. However, the FDA did not move them to Category 1 (the list of substances permitted for compounding), and neither peptide is FDA-approved nor do they have a recognized USP/NF monograph. This leaves them in a regulatory gray zone, where they’re neither explicitly prohibited nor authorized. The FDA has indicated that the following peptides will be discussed at its July 2026 advisory committee meeting regarding potential inclusion on the 503A bulks list:
- BPC-157
- KPV acetate
- TB-500 acetate
- MOTs-C
- Emideltide acetate
- Semax acetate
- Epitalon acetate
Until this review is completed, the compounding of these peptides is legally uncertain. Even if recategorization does occur, this does not mean that these peptides will be FDA-approved, only that they will be eligible for compounding.
Research-Only Peptides
Historically, many of the peptides above were labelled as “research use only” and not for human administration. While this label allows chemical suppliers to legally sell peptides for laboratory and experimental purposes, it does not authorize their use in humans. Despite this, the FDA determined that some online pharmacies were still marketing them for human administration and issued warning letters to multiple pharmacies over this issue.
Are you a prescriber looking for compounded medical solutions?
Please complete our new account form.
Research-only products are not manufactured to pharmaceutical standards and may not undergo stability, potency, and endotoxin testing, which are necessary safeguards for injectable drugs. They may also be manufactured in non-compliant facilities. Prescribing or dispensing such drugs may make a provider liable for any adverse events. This makes it critical to ensure that any prescribed peptides are sourced from a reputable 503A pharmacy that tests each batch.
FDA Regulatory Updates on Compounding Copies of Commercially Available Peptide-based Drugs
In addition to peptide re-categorization, the FDA also clarified its position on the compounding of GLP-1s, including semaglutide and tirzepatide. The FDA defined two criteria for what it considers compounding of “essentially a copy” of a commercially available drug:
- The compounded drug has the same API as a commercially available drug product in the same, similar, or easily substitutable strength.
- The compounded drug can be used by the same route of administration as a commercially available drug.
According to the FDA, the only exception to these two criteria is if “a prescriber determines and documents the compounded drug product contains a change that produces a significant difference from the commercially available drug product for an identified individual patient.” This means that the compounded version of a drug must provide a significant, clinically relevant difference for an individual patient compared with a commercially available drug.
Combining Multiple APIs
The FDA also mentioned that simply combining two APIs like semaglutide and vitamin B12 into a single preparation does not create a clinically distinct product in and of itself. In the semaglutide and vitamin B12 example, the FDA said it would consider a drug to be a copy of a commercially available drug if it has a similar strength (±10%) and uses the same route of administration.
Previously, the FDA’s language on this issue was a bit vague, but it has now provided more concrete guidance about what it considers to be compounding “regularly or in inordinate amounts”. The FDA has stated that it does not intend to take action against 503A pharmacies that fulfill four or fewer prescriptions per month for drugs that are essentially copies of commercially available products.
Sourcing and Compliance Considerations for Compounded Peptides
Now that 503B facilities can no longer compound FDA-approved GLP-1s in bulk since they are no longer in shortage and do not appear on the 503B bulks list, prescribers can turn to 503A compounding pharmacies to fulfill patient-specific prescriptions for these drugs. This still requires the prescriber to determine that a compounded version of a drug is necessary to elicit a significant clinical response within an individual patient.
Documentation and Clinical Justification
Given shifting regulations, prescribers should document as much as possible, including the specific clinical need for an individual patient. They should note why a commercial drug cannot be used, such as an individual patient’s allergy to an excipient or their need for a dose not commercially available.
Prescribers and pharmacies should also maintain records of prescriptions, batch certificates, and test results, such as the COA, which should list the drug’s identity, purity, and assay results. Providing these documents to inquiring patients enhances transparency and confidence.
Quality Assurance and Testing
Each compounded drug, including compounded peptides, should go through strict quality assurance protocols, which include sterile filtration or autoclaving, endotoxin testing, potency verification, and visual inspection for particulates.
Partnering with VLS Pharmacy for Approved Compounded Peptides
The regulatory landscape for compounded peptides continues to change. Prescribers should closely monitor FDA updates, especially after its July 2026 advisory committee meeting, and ensure that all prescribing decisions are well-documented and clinically justified.
Should any previously restricted peptides become eligible for compounding, VLS Pharmacy is ready to partner with prescribers by providing rigorously tested formulations, as well as copies of reports for stability, potency, and endotoxin testing for all of our compounded medications. This transparency helps ensure regulatory compliance and builds patient confidence by ensuring clarity about the composition, quality, and safety of injectable medications.
Please comment below with any thoughts or questions.
Reach out to our team if you have specific questions about our new automated compounding system and compounded medications for your patients. All medications from VLS Pharmacy and New Drug Loft are prepared in a lab that follows safety and quality standards per our status as a 503A pharmacy.
Read More…
- Tour our pharmacy
- Read more about our difference as a prestigious 503A compounding pharmacy
- It’s never been easier to submit your prescriptions! Place your order today
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE. The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site intends to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.
